Evidence map›Paper›PMID 40643729›Full record

Observational studyChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2025

Glucocorticoid use in paediatric posterior fossa tumour surgery and the occurrence of postoperative speech impairment.

Rebekka Sarup, Aske F Laustsen, Martin K Sørensen, Conor Mallucci, Barry Pizer, Kristian Aquilina, Emanuela Molinari, Magnus Aasved Hjort, Radek Frič, Per Nyman and 17 more

Registry-linked trialAbstract readObservational StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02300766 (Nordic Study of the Cerebellar Mutism Syndrome in Children With Brain Tumours of the Posterior Fossa), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02300766 recruitingnot on this map

Nordic Study of the Cerebellar Mutism Syndrome in Children With Brain Tumours of the Posterior Fossa

Typeobservational_patient_registrySponsorRigshospitalet, DenmarkRan2014 to 2028Enrolled2,000ConditionsInfratentorial Neoplasms, Mutism
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Rebekka SarupDepartment of Neurosurgery, The University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen E, Denmark.ORCID http://orcid.org/0009-0003-0834-5345
Aske F LaustsenDepartment of Neurosurgery, The University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen E, Denmark.ORCID http://orcid.org/0000-0002-3552-1346
Martin K SørensenDepartment of Neuroanesthesiology, The University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen E, Denmark.
Conor MallucciDepartment of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, E Prescot Rd, Liverpool, L14 5 AB, UK.
Barry PizerDepartment of Paediatric Oncology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
Kristian AquilinaDepartment of Neurosurgery, Great Ormond Street Hospital for Children, Great Ormond Street, London, WC1 N 3 JH, UK.ORCID http://orcid.org/0000-0001-7015-5196
Emanuela MolinariDepartment of Neurology, The Queen Elizabeth University Hospital, University of Glasgow, University Avenue, Glasgow, G12 8QQ, UK.ORCID http://orcid.org/0000-0003-2254-0852
Magnus Aasved HjortDepartment of Pediatric Hematology and Oncology, St Olavs Hospital, Postboks 3250 Torgarden, 7006, Trondheim, Norway.
Radek FričDepartment of Neurosurgery, Oslo University Hospital, Postboks 4950 Nydalen, Oslo, 0424, Norway.ORCID http://orcid.org/0000-0002-4267-0542
Per NymanDepartment of Biomedical and Clinical Sciences, Crown Princess Victoria Children's Hospital, Linköping University, Linköping, Sweden.ORCID http://orcid.org/0000-0001-8921-431X
Magnus SabelDepartment of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID http://orcid.org/0000-0002-3072-657X
Pelle NilssonDepartment of Neuroscience, Section of Neurosurgery, Uppsala University, Uppsala, Sweden.
Algimantas MatukevičiusDepartment of Neurosurgery, Lithuanian University of Health Sciences (LUHS), Kaunas, Lithuania.
Peter Hauser2nd Department of Pediatrics, Semmelweis University, Tűzoltó U. 7-9, 1094, Budapest, Hungary.ORCID http://orcid.org/0000-0002-8307-8975
Katalin Mudra2nd Department of Pediatrics, Semmelweis University, Tűzoltó U. 7-9, 1094, Budapest, Hungary.
Andrea CaraiDepartment of Neurosciences, Neurosurgery Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Julian ZipfelDepartment of Neurosurgery, Pediatric Neurosurgery, University Hospital Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany.
Eelco HovingPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-5587-0439
Kirsten van BaarsenPrincess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands.
Vladimír Beneš IIIrdDepartment of Neurosurgery, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.ORCID http://orcid.org/0000-0002-7269-0392
Andreas PeyrlDepartment of Pediatrics and Adolescent Medicine, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.ORCID http://orcid.org/0000-0002-5736-8231
Karsten NysomDepartment of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen E, Denmark.ORCID http://orcid.org/0000-0003-2935-0058
Astrid Marie SehestedDepartment of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen E, Denmark.
Kjeld SchmiegelowDepartment of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen E, Denmark.ORCID http://orcid.org/0000-0002-0829-4993
Marianne JuhlerDepartment of Neurosurgery, The University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen E, Denmark.ORCID http://orcid.org/0000-0003-2652-7495
Jonathan K Grønbæk *Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen E, Denmark. jonathan.kjaer.groenbaek@regionh.dk.ORCID http://orcid.org/0000-0002-7170-422X
René Mathiesen *Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Blegdamsvej 9, DK-2100, Copenhagen E, Denmark.ORCID http://orcid.org/0000-0003-3782-7776

Funding

Barncancerfonden,Sweden KP2019-0014Børnecancerfonden 2014-3, 2015-14, 2016-0143, 2018-3653, 2020-6732, 2021-7343
6 · The paper itself

Abstract

purposePostoperative speech impairment (POSI) is a core symptom of cerebellar mutism syndrome (CMS) and is a common complication after the resection of paediatric posterior fossa (PF) tumours. Preoperative glucocorticoids (pGC) are considered standard treatment to reduce tumour oedema; in addition, glucocorticoids are often administered intraoperatively (iGC) to reduce both postoperative nausea and vomiting. The study aims to investigate whether the occurrence of POSI may be associated with pGC and iGC.

methodsIn a prospective observational multicentre study, we included children with a PF tumour requiring either resection or open biopsy. The use of pGC and iGC, including drug type and dose, was registered. Postoperative speech status was classified as mutism, reduced speech, or habitual speech, where mutism and reduced speech were considered POSI of higher and lower severity, respectively. Proportional odds logistic regression with adjustment for tumour type, tumour location, and age was used to analyse the occurrence of POSI associated with glucocorticoids (GC).

resultsFrom August 2014 to November 2024, we recruited 810 children, of whom 605 were included in the primary analysis. We found no association between the use of GC (pGC nor iGC) and the occurrence of POSI. The result did not change when adjusting for tumour type, tumour location, and age. The analysis included both a comparison between using and not using pGC (OR 1.06 [95% CI 0.46 -2.49], reference level: use of pGC) and/or iGC (1.28 [0.58-2.82], reference level: use of iGC), and a dose-response analysis of the occurrence of POSI in relation to doubling the dose of GC (pGC OR 1.28 [0.84-1.98]; iGC OR 1.07 [0.62-1.82]).

conclusionOur study did not find evidence of a significant change in the occurrence of POSI with the use of pGC or iGC, but our results alone cannot rule out that the administration of pGC or iGC may have some effect. Therefore, our data do not call for a change in recommendations for the use of GC as protection against the development of POSI. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov (NCT02300766).  Date of registration: November 25, 2014.

Indexed as

GlucocorticoidsInfratentorial NeoplasmsPostoperative ComplicationsSpeech DisordersAdolescentChildChild, PreschoolFemaleHumansInfantMaleProspective StudiesGlucocorticoidsBrain neoplasmCerebellar mutism syndromeIntraoperativeNeurosurgeryPostoperative speech impairmentPreoperative

Identifiers

PMID40643729
PMCPMC12254087

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.